Literature DB >> 9113356

Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.

Y P Maneuf1, J M Brotchie.   

Abstract

The effects of the synthetic cannabinoid WIN 55,212-2 on forskolin-stimulated and basal adenosine 3':5'-cyclic monophosphate (cyclic AMP) accumulation in globus pallidus slices were investigated. WIN 55,212-2 caused a concentration-dependent decrease in forskolin-stimulated cyclic AMP accumulation in globus pallidus slices (maximum inhibition 36% for 30 microM). This effect was blocked by the cannabinoid receptor antagonist SR 141716A (100 microM). WIN 55,212-2 alone caused a concentration-dependent increase in cyclic AMP levels in unstimulated slices (maximum increase 52.6% for 100 microM). This effect was also blocked by SR 141716A (100 microM). In either forskolin-stimulated or unstimulated conditions SR 1417161A (100 microM) did not affect cyclic AMP levels.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9113356      PMCID： PMC1564638          DOI： 10.1038/sj.bjp.0701101

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

3.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids.

Authors:  Roger Cachope; Ken Mackie; Antoine Triller; John O'Brien; Alberto E Pereda
Journal:  Neuron       Date:  2007-12-20       Impact factor: 17.173

Review 6.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 7.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

8.  Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.

Authors:  Weimin Chen; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

Review 9.  New Insights in Cannabinoid Receptor Structure and Signaling.

Authors:  Lingyan Ye; Zheng Cao; Weiwei Wang; Naiming Zhou
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

10.  Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.

Authors:  F Rodríguez De Fonseca; M A Gorriti; A Bilbao; L Escuredo; L M García-Segura; D Piomelli; M Navarro
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.